OBJECTIVE: The aim of the study was to assess whether a simple, routinely available measure of antiretroviral therapy (ART) adherence predicts viral rebound at the next HIV viral load (VL) measurement in virally suppressed patients. METHODS: The analysis was performed on the Royal Free HIV Cohort, London, UK. Each 'drug coverage-viral load episode' (DCVL episode) was defined as a 6-month period immediately prior to a VL < or =50 HIV-1 RNA copies/mL (time-zero), during which the patient had been continuously on HAART, with all measured VLs < or =50 copies/mL. The next VL after time-zero was used to assess whether VL rebound (defined as >200 copies/mL) had occurred. Drug coverage, our measure of adherence, was calculated as the proportion of days in the 6-month period covered by a valid prescription for at least three antiretroviral drugs. RESULTS: A total of 376 (2.4%) VL rebounds occurred in 15 660 DCVL episodes among 1632 patients. Drug coverage was 100% for 32% of episodes, 95-99% for 16% of episodes and < or =60% for 10% of episodes. The risk ratio of rebound associated with a 10% increase in drug coverage, adjusted for potential confounding variables, was 0.93 (95% confidence interval 0.88-0.98). CONCLUSIONS: Antiretroviral drug coverage assessed at the time of VL measurement in patients with undetectable VL is potentially clinically useful for predicting VL rebound at the next VL measurement.
OBJECTIVE: The aim of the study was to assess whether a simple, routinely available measure of antiretroviral therapy (ART) adherence predicts viral rebound at the next HIV viral load (VL) measurement in virally suppressed patients. METHODS: The analysis was performed on the Royal Free HIV Cohort, London, UK. Each 'drug coverage-viral load episode' (DCVL episode) was defined as a 6-month period immediately prior to a VL < or =50 HIV-1 RNA copies/mL (time-zero), during which the patient had been continuously on HAART, with all measured VLs < or =50 copies/mL. The next VL after time-zero was used to assess whether VL rebound (defined as >200 copies/mL) had occurred. Drug coverage, our measure of adherence, was calculated as the proportion of days in the 6-month period covered by a valid prescription for at least three antiretroviral drugs. RESULTS: A total of 376 (2.4%) VL rebounds occurred in 15 660 DCVL episodes among 1632 patients. Drug coverage was 100% for 32% of episodes, 95-99% for 16% of episodes and < or =60% for 10% of episodes. The risk ratio of rebound associated with a 10% increase in drug coverage, adjusted for potential confounding variables, was 0.93 (95% confidence interval 0.88-0.98). CONCLUSIONS: Antiretroviral drug coverage assessed at the time of VL measurement in patients with undetectable VL is potentially clinically useful for predicting VL rebound at the next VL measurement.
Authors: Patricia Sweeney; Lytt I Gardner; Kate Buchacz; Pamela Morse Garland; Michael J Mugavero; Jeffrey T Bosshart; R Luke Shouse; Jeanne Bertolli Journal: Milbank Q Date: 2013-07-08 Impact factor: 4.911
Authors: James H McMahon; Michael R Jordan; Karen Kelley; Silvia Bertagnolio; Steven Y Hong; Christine A Wanke; Sharon R Lewin; Julian H Elliott Journal: Clin Infect Dis Date: 2011-01-18 Impact factor: 9.079
Authors: David B Hanna; Uriel R Felsen; Mindy S Ginsberg; Barry S Zingman; Robert S Beil; Donna C Futterman; Howard D Strickler; Kathryn Anastos Journal: AIDS Res Hum Retroviruses Date: 2016-03-17 Impact factor: 2.205
Authors: Jemma L O'Connor; Edward M Gardner; Sharon B Mannheimer; Alan R Lifson; Stefan Esser; Edward E Telzak; Andrew N Phillips Journal: J Infect Dis Date: 2012-11-29 Impact factor: 5.226
Authors: Victoria Johnston; Katherine Fielding; Salome Charalambous; Mildred Mampho; Gavin Churchyard; Andrew Phillips; Alison D Grant Journal: PLoS One Date: 2012-05-29 Impact factor: 3.240